Results 151 to 160 of about 2,390,694 (316)
Evidence-based medicine and the practicing clinician
, 1999 Finlay A. McAlister +3 more
openalex +2 more sources
Stochastic variation in the FOXM1 transcription program mediates replication stress tolerance
Molecular Oncology, EarlyView.Cellular heterogeneity is a major cause of drug resistance in cancer. Segeren et al. used single‐cell transcriptomics to investigate gene expression events that correlate with sensitivity to the DNA‐damaging drugs gemcitabine and prexasertib. They show that dampened expression of transcription factor FOXM1 and its target genes protected cells against ...
Hendrika A. Segeren +4 more
wiley +1 more source
All members of primary care team are aware of importance of evidence based medicine [PDF]
, 1998 Nicola A. Hagdrup +3 more
openalex +1 more source
Molecular Oncology, EarlyView.The study evaluated the function and therapeutic implications of PRAME in basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The findings demonstrate that PRAME impairs keratinocyte differentiation pathways. Furthermore, PRAME impairs anticancer response to retinoid compounds in BCC and SCC cells.
Brandon Ramchatesingh +6 more
wiley +1 more source
Evidence-Based Medicine: Old French Wine with a New Canadian Label?
, 1997 P. K. Rangachari
openalex +1 more source
Classification of acute myeloid leukemia based on multi‐omics and prognosis prediction value
Molecular Oncology, EarlyView.The Unsupervised AML Multi‐Omics Classification System (UAMOCS) integrates genomic, methylation, and transcriptomic data to categorize AML patients into three subtypes (UAMOCS1‐3). This classification reveals clinical relevance, highlighting immune and chromosomal characteristics, prognosis, and therapeutic vulnerabilities.
Yang Song +13 more
wiley +1 more source
Primary extranodal diffuse large B‐cell lymphoma: Molecular features, treatment, and prognosis
Aging and Cancer, Volume 3, Issue 3-4, Page 133-146, September-December 2022., 2022 One‐third of DLBCL arises from extranodal organs and is challenging to manage. Molecular features are critical to elucidate the differences in clinical features, predict the disease prognosis, and improve effective targeted therapeutic strategies. Abstract Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin's lymphoma and ...
Si‐Yuan Chen +3 more
wiley +1 more source
Evidence-Based Emergency Medicine: Updates, Feedback, and Links [PDF]
, 1999 Peter C. Wyer, William H. Cordell
openalex +1 more source
Adverse prognosis gene expression patterns in metastatic castration‐resistant prostate cancer
Molecular Oncology, EarlyView.We aggregated a cohort of 1012 mCRPC tissue samples from 769 patients and investigated the association of gene expression‐based pathways with clinical outcomes. Loss of AR signaling, high proliferation, and a glycolytic phenotype were independently prognostic for poor outcomes, and an adverse transcriptional feature score incorporating these pathways ...
Marina N. Sharifi +26 more
wiley +1 more source